Veille Scientifique

Patrice PIENKOWSKI
Coordinateur

 Après 3 ans de bons et loyaux services, la veille scientifique va s’arrêter ; voici les derniers articles sélectionnés à votre intention.
 
Nous avons pris cette décision difficile suite au constat d’un investissement très important pour un service rendu finalement incertain, comme l’attestent les statistiques de fréquentation de la rubrique sur ce site. 
 
Je remercie tous ceux et celles qui se sont investis dans la durée pour assurer la réussite du projet, à commencer par les responsables des groupes de veille : Emmanuel Coron (Endoscopie), Roger Faroux (Cancérologie), Pauline Jouët (Gastro-entérologie et proctologie), Stéphane Nahon (MICI), Vinciane Rebours (Pancréatologoie) et Christine Silvain (Hépatologie), mais aussi et surtout, tous les veilleurs anonymes pour la grande qualité de leur travail, leur compétence et leur persévérance.
Le travail de veille bibliographique ne disparait pas complètement malgré tout, grâce aux GastroScoops dont la fréquence va augmenter avec un objectif de diffusion hebdomadaire ; il s’agit d’un travail rédactionnel différent avec une analyse d’article plus approfondie et structurée, porteur de message important.

Restez donc fidèles à ces rubriques et visitez régulièrement le site de la SNFGE toujours très riche d’enseignements et d’informations.

Très cordialement.

Dr Patrice PIENKOWSKI

 

Six groupes animés par un responsable se chargent de ce travail tous les mois :

Cancers Endoscopie

Foie/
VB/
Addicto

 Gastro/
Procto/
Nutrition		 MICI Pancréas
A. LIEVRE V. VALANTIN I. ROSA P. JOUET S. NAHON V. REBOURS

V. HAUTEFEUILLE
N. WILLIET
N. FARES
Y. TOUCHEFEU

A. CULETTO
Y. LEBALEUR
G. PERROD
V. VALANTIN

C. BARRAULT
P. DUKAN
N. GANNE-CARRIE
PE. RAUTOU

H. DAMON
T. HIGUERO
V. de PARADES
F. ZERBIB

V. ABITBOL
P. FAURE
M. FUMERY
D LAHARIE
P. SEKSIK

M. CAMUS-DUBOC
E. GELSI
L. de MESTIER


Nous espérons de ce nouvel outil qu’il vous aide à accéder rapidement et sélectivement aux données nouvelles de notre discipline selon vos sujets d’intérêt, qu’ils soient larges ou très spécifiques.

Revuetrier par ordre croissant Titre Date Coup de coeur Thématique
Clinical Gastroenterology and Hepatology Non-Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. mai. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Association Between Consumption of Red and Processed Meat and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis avr. 17 3 ♥ Pancréas/voies bilaires
Clinical Gastroenterology and Hepatology Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. avr. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Education, Employment, Income, and Marital Status Among Adults Diagnosed With Inflammatory Bowel Diseases During Childhood or Adolescence avr. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Biologics Delay Progression of Crohn’s Disease, but Not Early Surgery, in Children sep. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Features of Patients With Crohn's Disease and Hidradenitis Suppurativa. Jan. 16 3 ♥ MICI
Clinical Gastroenterology and Hepatology Increasing Prescription of Opiates and Mortality in Patients With Inflammatory Bowel Diseases in England. mai. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Dietary Factors Reduce Risk of Acute Pancreatitis in a Large Multiethnic Cohort fév. 17 2 ♥ Pancréas
Clinical Gastroenterology and Hepatology Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. avr. 18 3 ♥ MICI
Clinical Gastroenterology and Hepatology Higher Growth Rate of Branch Duct Intraductal Papillary Mucinous Neoplasms Associates With Worrisome Features sep. 18 3 ♥ Pancréas/Voies biliaires
Clinical Gastroenterology and Hepatology Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists fév. 17 3 ♥ MICI
Clinical Gastroenterology and Hepatology Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis fév. 17 3 ♥ MICI
Inflammatory Bowel Diseases Frequency and Risk Factors of Clostridium difficile Infection in Hospitalized Patients With Pouchitis: A Population-based Study Gaurav avr. 17 3 ♥ MICI
Inflammatory Bowel Diseases The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease juin. 17 3 ♥ MICI
Inflammatory Bowel Diseases 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial mai. 17 2 ♥ MICI
Inflammatory Bowel Diseases Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort. oct. 18 3 ♥ Coloproctologie
Inflammatory Bowel Diseases Defining the Most Appropriate Delivery Mode in Women with Inflammatory Bowel Disease: A Systematic Review. mai. 17 4 ♥ Coloproctologie
Inflammatory Bowel Diseases Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Cro sep. 17 3 ♥ MICI
Inflammatory Bowel Diseases Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. mai. 16 4 ♥ MICI
Inflammatory Bowel Diseases Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab oct. 17 4 ♥ MICI
Inflammatory Bowel Diseases Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. oct. 17 4 ♥ Coloproctologie
Inflammatory Bowel Diseases Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Jan. 17 2 ♥ MICI
Inflammatory Bowel Diseases Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease juil. 17 3 ♥ MICI
Inflammatory Bowel Diseases The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. fév. 17 2 ♥ MICI
Inflammatory Bowel Diseases Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn’s Disease aoû. 17 3 ♥ MICI

Pages